Veeva Vault CDMS Selected by Idorsia to Modernize Clinical Data Management

Fast-Growing Biopharmaceutical Company Will Use Vault CDMS for All New Trials

Barcelona, ​​Spain, February 15, 2022 /PRNewswire/ — Veeva Systems (NYSE: VEEV) today announced that Idorsia Pharmaceuticals Ltd (SIX: IDIA) has expanded its use of Veeva Vault Clinical Suite apps to include CDMS Veeva Vault for electronic data capture (EDC) and coding. Idorsia is focused on the discovery, development and commercialization of innovative therapies and needed a modern data management system to support in-house study execution. Vault CDMS provides a suite of advanced cloud applications that will enable Idorsia to accelerate study builds and accelerate trial execution.

“With the increasing complexity of trial design and the increase in clinical data sources, a next-generation clinical data management system is essential,” said Vincent Roland, Associate Director, Data Management Programming at Idorsia. “We are excited to expand our partnership with Veeva to bring more speed and agility to our clinical trials.”

Situated at Switzerland, Idorsia is a fast-growing biopharmaceutical company with a broad portfolio of new drugs in its pipeline. The company is moving from outsourced clinical data management to an in-house model and needs flexible cloud technology that allows its team to create and maintain studies on a wide range of products. With Vault CDMS, clinical teams at Idorsia will have the ability to build studies independently, make mid-study changes without data migration, and expedite data cleaning and review.

“Idorsia is a forward-thinking company embracing digital systems to advance data management,” said Richard Young, Vice President, Strategy, Veeva Vault CDMS. “As a trusted partner, we are proud to support their clinical systems strategy with modern applications that can keep up with the pace and complexity of today’s studies.”

Vault CDMS is part of Vault Clinical Suite, the industry’s first cloud-based platform that unifies clinical data management and clinical operations. In addition to selecting Vault CDMS, Idorsia uses Veeva Vault CTMS and Veeva Vault eTMF to manage trial content and data on a single cloud platform. Together, these Vault Clinical Suite applications will streamline execution and enable seamless sharing of information between trials.

Additional information
To learn more about Veeva Vault CDMS, visit: veeva.com/eu/VaultCDMS
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow @veeva_eu on Twitter: twitter.com/veeva_eu

About Idorsia
Idorsia Ltd seeks more – We have more ideas, we see more opportunities and we want to help more patients. To achieve this, we will develop Idorsia into a leading biopharmaceutical company with a strong scientific core.

Based near Basel, Switzerland – European biotechnology hub – Idorsia specializes in the discovery, development and marketing of small molecules to transform the horizon of therapeutic options. Idorsia has a broad pipeline of innovative drugs in the pipeline, an experienced team of professionals spanning all disciplines from laboratory to bedside, state-of-the-art facilities and a strong track record – the constellation ideal for translating R&D efforts into commercial success.

Idorsia was listed on the SIX Swiss Exchange (stock symbol: IDIA) in June 2017 and has more than 1000 highly qualified specialists dedicated to achieving our ambitious goals.

About Veeva systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence and customer success, Veeva serves more than 1,000 customers, ranging from the world’s largest pharmaceutical companies to emerging biotechs. As a public benefit company, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com/eu.

Logo- https://mma.prnewswire.com/media/1488285/Veeva_Systems_Logo.jpg

SOURCE Veeva Systems